Brought to you by 
AZ out-licenses cardio drug rights to CMS, Tibet Rhodiola; gets $500mm
28 Apr 2016
Executive Summary
AstraZeneca PLC off-loaded rights for two cardiovascular drugs to China Medical System Holdings Ltd. (CMS) and one of its affiliates, Tibet Rhodiola Pharmaceutical Holding Co. (Tibet Rhodiola is minority-owned by CMS, which is its largest shareholder.)
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ out-licenses cardio drug rights to CMS, Tibet Rhodiola; gets $500mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice